Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504195 | 1.00 | EGFR (1.00) | EGFRKDM4EHTTALDH1A1TP53 | |
| SCHEMBL27941975 | 0.89 | EGFR (0.80) | EGFRKDM4EHTTALDH1A1TP53 | |
| SCHEMBL1403684 | 0.83 | EGFR (1.00) | EGFRKDM4EHTTALDH1A1MAPT | |
| SCHEMBL28178788 | 0.81 | EGFR (0.67) | EGFRKDM4EALDH1A1TP53MAPT | |
| SCHEMBL8644295 | 0.78 | PIK3CA (0.73) | EGFRKDM4EPIK3CDPIK3CAFGFR4 | |
| SCHEMBL29723993 | 0.76 | EGFR (0.61) | EGFRKDM4EPIK3CDPIK3CAFGFR4 | |
| SCHEMBL11162210 | 0.76 | EGFR (0.61) | EGFRKDM4EHTTALDH1A1TP53 | |
| SCHEMBL30503636 | 0.76 | EGFR (0.61) | EGFRKDM4EHTTALDH1A1TP53 | |
| SCHEMBL4147243 | 0.75 | EGFR (0.60) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL276644 | 0.75 | EGFR (0.60) | EGFRPIK3CDPIK3CAFGFR4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104876882-B | 6- amino-quinazoline compounds and application | 浙江工业大学 | 2018-05-08 | — | — | CN | claimed |
| CN-104876882-A | 6-aminoquinazoline compound and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2015-09-02 | — | — | CN | claimed |
| CN-102850397-A | Multi-target antitumor compounds and preparation method and application thereof | UNIV BEIJING | 2013-01-02 | — | — | CN | claimed |
| CN-1177833-C | Substd. quinazoline derivatives | ���Ͽعɹ�˾ | 2004-12-01 | — | — | CN | claimed |
| US-5760041-A | 4-aminoquinazoline EGFR Inhibitors | AMERICAN CYANAMID COMPANY (US) | 1998-06-02 | — | — | US | claimed |
| CN-1161330-A | Substd. quinazoline derivatives | AMERICAN CYANAMID CO (US) | 1997-10-08 | — | — | CN | claimed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | claimed |
| US-20260001851-A1 | TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU CONCORD BIOTECHNOLOGY CO LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | JIANGSU CONCORD BIOTECHNOLOGY CO., LTD (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-4580639-A1 | TREATMENT OF FAMILIAL ADENOMATOUS POLYOPSIS USING A 13-MEMBERED MACROLIDE | Zikani Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-120152721-A | Treatment of familial adenomatous polyposis with 13-membered macrolides | 齐卡尼治疗股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| CN-1218456-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 1999-06-02 | — | — | CN | disclosed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| CN-1161330-A | Substd. quinazoline derivatives | AMERICAN CYANAMID CO (US) | 1997-10-08 | — | — | CN | disclosed |
| CN-1149604-A | Water insoluble azoie color based on amino quinazoline dione | HOECHST AG (DE) | 1997-05-14 | — | — | CN | disclosed |
| US-5240928-A | Hypotensive agents | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001851-A1 | TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL APPLICATION THEREOF | ABL1, ERBB2, ALK | EGFR 7/4885KDM4E 1053/4885HTT 3633/4885 |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | EGFR 1566/4885KDM4E 615/4885HTT 54/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | EGFR 668/4885KDM4E 3382/4885HTT 4577/4885 |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | SRC, ABL1, ERBB2 | EGFR 9/4885KDM4E 1345/4885HTT 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.